Rath et al. analyzed peripheral blood and colonic biopsy samples for CD4+ T cell subpopulations, cytokine production, and mRNA and protein expression including the α4β7 integrin and MAdCAM-1 to investigate factors associated with VDZ efficacy in patients with IBD and revealed a significant difference in genetic signatures at baseline between subjects with and without clinical remission at week 1421. Here, CD4 is linked to inflammatory bowel disease.